Studies of targeted therapies in PNET have, to date, focused primarily on inhibitors of the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin- (mTOR) signaling pathways. The gene discussed is VEGFA; the disease is primitive neuroectodermal tumor.